Long-acting GLP-1 Therapy - Global Top Players Market Share and Ranking 2025- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > Long-acting GLP-1 Therapy - Global Top Players Market Share and Ranking 2025

Long-acting GLP-1 Therapy - Global Top Players Market Share and Ranking 2025

Publication Date: 2025-11-16
Report Id: 2778016
Industry: Pharma & Healthcare
Report Page: 94
Chart: 93

PDF Download

Publication Date: 2025-11-16
Report Id: 2778016
Industry: Pharma & Healthcare
Report Page: 94
Chart: 93

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Long-acting GLP-1 Therapy Definition
1.2 Global Long-acting GLP-1 Therapy Market Size and Forecast
1.2.1 By Consumption Value, Global Long-acting GLP-1 Therapy Market Size, 2020-2031
1.2.2 By Sales Quantity, Global Long-acting GLP-1 Therapy Market Size, 2020-2031
1.2.3 Global Long-acting GLP-1 Therapy Average Selling Price (ASP), 2020-2031
1.3 China Long-acting GLP-1 Therapy Market Size and Forecast
1.3.1 By Consumption Value, China Long-acting GLP-1 Therapy Market Size, 2020-2031
1.3.2 By Sales Quantity, China Long-acting GLP-1 Therapy Market Size, 2020-2031
1.3.3 China Long-acting GLP-1 Therapy Average Selling Price (ASP), 2020-2031
1.4 Share of China Long-acting GLP-1 Therapy Market with Respect to the Global Market
1.4.1 By Consumption Value, China Long-acting GLP-1 Therapy Market Share in Global, 2020-2031
1.4.2 By Sales Quantity, China Long-acting GLP-1 Therapy Market Share in Global, 2020-2031
1.4.3 Long-acting GLP-1 Therapy Market Size: China VS Global, 2020-2031
1.5 Long-acting GLP-1 Therapy Market Dynamics
1.5.1 Long-acting GLP-1 Therapy Market Drivers
1.5.2 Long-acting GLP-1 Therapy Market Restraints
1.5.3 Long-acting GLP-1 Therapy Industry Trends
1.5.4 Long-acting GLP-1 Therapy Industry Policy

2 Global Leading Manufacturers and Market Share
2.1 By Revenue of Long-acting GLP-1 Therapy, Global Market Share by Company, 2020-2025
2.2 By Sales Quantity of Long-acting GLP-1 Therapy, Global Market Share by Company, 2020-2025
2.3 Long-acting GLP-1 Therapy Average Selling Price (ASP) by Company, 2020-2025
2.4 Global Long-acting GLP-1 Therapy Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global Long-acting GLP-1 Therapy Concentration Ratio
2.6 Global Long-acting GLP-1 Therapy Mergers & Acquisitions, Expansion Plans
2.7 Global Long-acting GLP-1 Therapy Manufacturers Product Type
2.8 Head Office and Long-acting GLP-1 Therapy Production Site of Key Manufacturer
2.9 Long-acting GLP-1 Therapy Capacity of Major Manufacturers and Future Plan

3 China Leading Manufacturers and Market Share
3.1 By Revenue of Long-acting GLP-1 Therapy, China Market Share by Company, 2020-2025
3.2 By Sales Quantity of Long-acting GLP-1 Therapy, China Market Share by Company, 2020-2025
3.3 China Long-acting GLP-1 Therapy Long-acting GLP-1 Therapy Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Global Producing Regions
4.1 Global Long-acting GLP-1 Therapy Capacity, Output and Capacity Utilization, 2020-2031
4.2 Global Long-acting GLP-1 Therapy Capacity by Region
4.3 Global Long-acting GLP-1 Therapy Production & Forecast by Region, 2020 VS 2024 VS 2031
4.4 Global Long-acting GLP-1 Therapy Production by Region, 2020-2031
4.5 Global Long-acting GLP-1 Therapy Production Market Share & Forecast by Region, 2020-2031

5 Industry Chain Analysis
5.1 Long-acting GLP-1 Therapy Industry Chain
5.2 Long-acting GLP-1 Therapy Upstream Analysis
5.2.1 Long-acting GLP-1 Therapy Core Raw Materials
5.2.2 Main Manufacturers of Long-acting GLP-1 Therapy Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 Long-acting GLP-1 Therapy Production Mode
5.6 Long-acting GLP-1 Therapy Procurement Model
5.7 Long-acting GLP-1 Therapy Industry Sales Model and Sales Channels
5.7.1 Long-acting GLP-1 Therapy Sales Model
5.7.2 Long-acting GLP-1 Therapy Typical Distributors

6 Sights by Type
6.1 Long-acting GLP-1 Therapy Classification by Type
6.1.1 Injection
6.1.2 Oral
6.2 by Type, Global Long-acting GLP-1 Therapy Consumption Value & CAGR, 2020 VS 2024 VS 2031
6.3 by Type, Global Long-acting GLP-1 Therapy Consumption Value, 2020-2031
6.4 by Type, Global Long-acting GLP-1 Therapy Sales Quantity, 2020-2031
6.5 by Type, Global Long-acting GLP-1 Therapy Average Selling Price (ASP), 2020-2031

7 Sights by Feature
7.1 Long-acting GLP-1 Therapy Classification by Feature
7.1.1 GLP-1 Receptor Agonists
7.1.2 Co-agonists
7.2 by Feature, Global Long-acting GLP-1 Therapy Consumption Value & CAGR, 2020 VS 2024 VS 2031
7.3 by Feature, Global Long-acting GLP-1 Therapy Consumption Value, 2020-2031
7.4 by Feature, Global Long-acting GLP-1 Therapy Sales Quantity, 2020-2031
7.5 by Feature, Global Long-acting GLP-1 Therapy Average Selling Price (ASP), 2020-2031

8 Sights by Channel
8.1 Long-acting GLP-1 Therapy Classification by Channel
8.1.1 Online Sales
8.1.2 Offline Sales
8.2 by Channel, Global Long-acting GLP-1 Therapy Consumption Value & CAGR, 2020 VS 2024 VS 2031
8.3 by Channel, Global Long-acting GLP-1 Therapy Consumption Value, 2020-2031
8.4 by Channel, Global Long-acting GLP-1 Therapy Sales Quantity, 2020-2031
8.5 by Channel, Global Long-acting GLP-1 Therapy Average Selling Price (ASP), 2020-2031

9 Sights by Application
9.1 Long-acting GLP-1 Therapy Segment by Application
9.1.1 Type 2 Diabetes
9.1.2 Obesity/Weight Management
9.1.3 Other
9.2 by Application, Global Long-acting GLP-1 Therapy Consumption Value & CAGR, 2020 VS 2024 VS 2031
9.3 by Application, Global Long-acting GLP-1 Therapy Consumption Value, 2020-2031
9.4 by Application, Global Long-acting GLP-1 Therapy Sales Quantity, 2020-2031
9.5 by Application, Global Long-acting GLP-1 Therapy Price, 2020-2031

10 Sales Sights by Region
10.1 By Region, Global Long-acting GLP-1 Therapy Consumption Value, 2020 VS 2024 VS 2031
10.2 By Region, Global Long-acting GLP-1 Therapy Consumption Value, 2020-2031
10.3 By Region, Global Long-acting GLP-1 Therapy Sales Quantity, 2020-2031
10.4 North America
10.4.1 North America Long-acting GLP-1 Therapy Market Size & Forecasts, 2020-2031
10.4.2 By Country, North America Long-acting GLP-1 Therapy Market Size Market Share
10.5 Europe
10.5.1 Europe Long-acting GLP-1 Therapy Market Size & Forecasts, 2020-2031
10.5.2 By Country, Europe Long-acting GLP-1 Therapy Market Size Market Share
10.6 Asia Pacific
10.6.1 Asia Pacific Long-acting GLP-1 Therapy Market Size & Forecasts, 2020-2031
10.6.2 By Country/Region, Asia Pacific Long-acting GLP-1 Therapy Market Size Market Share
10.7 South America
10.7.1 South America Long-acting GLP-1 Therapy Market Size & Forecasts, 2020-2031
10.7.2 By Country, South America Long-acting GLP-1 Therapy Market Size Market Share
10.8 Middle East & Africa

11 Sales Sights by Country Level
11.1 By Country, Global Long-acting GLP-1 Therapy Market Size & CAGR, 2020 VS 2024 VS 2031
11.2 By Country, Global Long-acting GLP-1 Therapy Consumption Value, 2020-2031
11.3 By Country, Global Long-acting GLP-1 Therapy Sales Quantity, 2020-2031
11.4 United States
11.4.1 United States Long-acting GLP-1 Therapy Market Size, 2020-2031
11.4.2 by Type, United States Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.4.3 by Application, United States Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.5 Europe
11.5.1 Europe Long-acting GLP-1 Therapy Market Size, 2020-2031
11.5.2 by Type, Europe Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.5.3 by Application, Europe Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.6 China
11.6.1 China Long-acting GLP-1 Therapy Market Size, 2020-2031
11.6.2 by Type, China Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.6.3 by Application, China Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.7 Japan
11.7.1 Japan Long-acting GLP-1 Therapy Market Size, 2020-2031
11.7.2 by Type, Japan Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.7.3 by Application, Japan Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.8 South Korea
11.8.1 South Korea Long-acting GLP-1 Therapy Market Size, 2020-2031
11.8.2 by Type, South Korea Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.8.3 by Application, South Korea Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.9 Southeast Asia
11.9.1 Southeast Asia Long-acting GLP-1 Therapy Market Size, 2020-2031
11.9.2 by Type, Southeast Asia Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.9.3 by Application, Southeast Asia Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.10 India
11.10.1 India Long-acting GLP-1 Therapy Market Size, 2020-2031
11.10.2 by Type, India Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.10.3 by Application, India Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.11 Middle East & Africa
11.11.1 Middle East & Africa Long-acting GLP-1 Therapy Market Size, 2020-2031
11.11.2 by Type, Middle East & Africa Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031
11.11.3 by Application, Middle East & Africa Long-acting GLP-1 Therapy Sales Quantity Market Share, 2024 VS 2031

12 Manufacturers Profile
12.1 Novo Nordisk
12.1.1 Novo Nordisk Company Information, Head Office, Market Area, and Industry Position
12.1.2 Novo Nordisk Long-acting GLP-1 Therapy Models, Specifications, and Application
12.1.3 Novo Nordisk Long-acting GLP-1 Therapy Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.1.4 Novo Nordisk Company Profile and Main Business
12.1.5 Novo Nordisk Recent Developments
12.2 Eli Lilly
12.2.1 Eli Lilly Company Information, Head Office, Market Area, and Industry Position
12.2.2 Eli Lilly Long-acting GLP-1 Therapy Models, Specifications, and Application
12.2.3 Eli Lilly Long-acting GLP-1 Therapy Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.2.4 Eli Lilly Company Profile and Main Business
12.2.5 Eli Lilly Recent Developments
12.3 AstraZeneca (legacy)
12.3.1 AstraZeneca (legacy) Company Information, Head Office, Market Area, and Industry Position
12.3.2 AstraZeneca (legacy) Long-acting GLP-1 Therapy Models, Specifications, and Application
12.3.3 AstraZeneca (legacy) Long-acting GLP-1 Therapy Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
12.3.4 AstraZeneca (legacy) Company Profile and Main Business
12.3.5 AstraZeneca (legacy) Recent Developments

13 Conclusion

14 Appendix
14.1 Research Methodology
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Market Estimation Model
14.4 Disclaimer

According to YH Research, the global market for Long-acting GLP-1 Therapy should grow from US$ 24577 million in 2024 to US$ 71590 million by 2031, with a CAGR of 17.8% for the period of 2025-2031.

The strategic recalibration of 2025 U.S. tariff mechanisms is redefining global economic governance norms. This study deciphers the transmission mechanisms of tariff escalation pathways and global policy responses on corporate investment strategies, regional trade networks, and critical material supply architectures.

Long-acting GLP-1 Therapy

According to YH Research, the global market for Long-acting GLP-1 Therapy should grow from US$ 24577 million in 2024 to US$ 71590 million by 2031, with a CAGR of 17.8% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

Long-acting GLP-1 therapy means GLP-1–receptor–based medicines engineered to last a week (or longer) so they’re dosed once weekly rather than daily/twice-daily. They give steadier receptor activation for type 2 diabetes control and chronic weight management by boosting glucose-dependent insulin, slowing gastric emptying, and suppressing appetite. In 2024, global Long-acting GLP-1 Therapy production reached approximately 45234 K Unit, with an average global market price of around US$ 511 per unit.

Market outlook: GLP-1 therapies are set for sustained hypergrowth over the next 5–10 years as obesity care globalizes beyond type 2 diabetes, supported by compelling outcomes data, expanding payor coverage, and strong consumer pull for chronic weight management.

Industry chain (upstream→midstream): Upstream consists of peptide APIs (solid-phase synthesis, high-capacity preparative chromatography, PEGylation/lipidation linkers), device components (autoinjectors, pens, safety needles), and excipients, while midstream innovators integrate long-acting analog design, fill-finish, device pairing, and global regulatory/CMC to deliver branded combination drug–device products.

Downstream & ecosystem: Downstream demand flows through endocrinology and primary-care channels, obesity clinics, digital telehealth platforms, and employer/payer programs, with adherence, supply continuity, and step-therapy rules shaping real-world volumes and with compounding and biosimilar entry emerging as price/modality pressure over time.

Growth drivers & constraints: Growth is propelled by superior cardiometabolic outcomes (A1c, weight loss, CV risk signals), label and geography expansion, and pipeline next-gen incretin combos (GLP-1/GIP/GCGR), while constraints include manufacturing scale for complex peptides, device capacity, reimbursement variability, GI tolerability/attrition, and eventual price erosion from competition and biosimilars.

Economics (gross margins): At scale, branded GLP-1 drug–device products typically achieve ~75–90% gross margins for originators (high list prices, efficient peptide and device supply), ~20–35% for contract manufacturers/device suppliers, and ~10–20% for distribution/dispensing, with blended margins compressing over time as pricing pressure, rebates, and competitive entrants increase.

This report studies and analyses global Long-acting GLP-1 Therapy status and future trends, helps the client to determine the Long-acting GLP-1 Therapy market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Long-acting GLP-1 Therapy, and provides market size (in K Units & US$ million) and Year-over-Year growth, considering 2024 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Long-acting GLP-1 Therapy market size, history data 2020-2025, and forecast data 2026-2031, (US$ million) & (K Units)
(2) Global Long-acting GLP-1 Therapy sales, revenue, price by company, market share and industry ranking 2020-2025, (US$ million) & (K Units)
(3) China Long-acting GLP-1 Therapy sales, revenue, price by company, market share and industry ranking 2020-2025, (US$ million) & (K Units)
(4) Global Long-acting GLP-1 Therapy key consuming regions, consumption quantity, consumption value and demand structure
(5) Global Long-acting GLP-1 Therapy key producing regions, capacity, production, and year over year growth
(6) Long-acting GLP-1 Therapy industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Novo Nordisk
Eli Lilly
AstraZeneca (legacy)

Market segment by Type, covers
Injection
Oral

Market segment by Feature, covers
GLP-1 Receptor Agonists
Co-agonists

Market segment by Channel, covers
Online Sales
Offline Sales

Market segment by Application, can be divided into
Type 2 Diabetes
Obesity/Weight Management
Other

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Long-acting GLP-1 Therapy product scope, global sales quantity, value and average price, China sales quantity, value and average price, development opportunities, challenges, trends, and policies.
Chapter 2: Global Long-acting GLP-1 Therapy market share and ranking of major manufacturers, sales quantity, revenue, average price, 2020-2025
Chapter 3: China Long-acting GLP-1 Therapy market share and ranking of major manufacturers, sales quantity, revenue, average price, 2020-2025
Chapter 4: Global key producing regions of Long-acting GLP-1 Therapy, percent & CAGR, 2020-2031
Chapter 5: Long-acting GLP-1 Therapy industry chain, upstream, medium-stream, and downstream.
Chapter 6: Segment by Type, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 7: Segment by Application, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 8: Segment in regional level, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 9: Segment in country level, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 10: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, sales quantity, average price, revenue, gross margin.